BluntForceOptions
Posted - 04/29/24
$SLRN Acelyrin will be hosting a CC on Mon, May 13 at 4:30 pm ET to review Q1 2024 financial results and provide a corp update. A webcast will be available on the 'Events & Presentations' section of the co's website.
Stock_Titan
Posted - 04/29/24
$SLRN ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
https://www.stocktitan.net/news/SLRN/acelyrin-inc-to-report-first-quarter-2024-financial-results-and-ii3u4xwfgvkp.html
BluntForceOptions
Posted - 04/26/24
$SLRN Food for thought: I don't invest in co's based solely on T/O speculation, but considering Acelyrin's laughably low 418M MC & -307M EV, it's clear there's a unique opportunity for those looking to expand. With a BOD rich in M&A experience, it's definitely not out of the question to think major players who missed out on $HZNP to $AMGN could be taking a serious look. Acelyrin boasts robust, late-stage programs and a promising anti-cKIT monoclonal antibody (w/a lead indication for Chronic Urticaria (CU), a market expected to grow to greater than $5.8B globally by 2030), that could be exactly what co's like $SNY need to bolster their portfolios. IMO, the combo of Acelyrin's advanced PL and obvious undervaluation forms a rare alignment that could spark interest from larger bios seeking significant, strategic additions at a value-driven entry point. Time will tell, but in the meantime, I remain extremely bullish and anticipating a strong reversal in the near future. Blessings to all.
TradeDeskAnalytics
Posted - 04/26/24
$SLRN Buy now, Lambo’ later. This one’s a no-brainer. Volatility is a normal part of the process. Stocks overshoot in both directions all the time which creates the best opportunities. If you’re looking for instant gratification, you’re in the wrong business. As we head into anticipated 2H ’24 catalysts, the stock will be up huge from here. Mark it!
EquityInvest
Posted - 04/26/24
$SLRN fck this loser company!!! CEO is autistic and questionable 🤨 hahaha!!! He/she should climb back into whole whence they came no good at horizon therapeutic and took losers from there to start crap and steal invest lie $$$ too easy to get rich shorting!!!!!!’
EquityInvest
Posted - 04/26/24
@TradeDeskAnalytics should have kidtened!! Another 30% drop since my post!!! $SLRN the company I love to hate should short it with everything!!!! There is something wrong with the CEO!! Probably autism… or just reality that he/she is just a loser plain and simple!!!!
Stonkey
Posted - 04/25/24
$SLRN Hopeless POS going straight to zero...
BluntForceOptions
Posted - 04/24/24
$SLRN The stock is a powder keg, currently at outrageously oversold levels and poised for an epic reversal.
elbowcrooker
Posted - 04/23/24
$SLRN took at 500 share starter at 4.59. Let's go
Stonkey
Posted - 04/23/24
$SLRN Hopeless POS.....
Thuebs89
Posted - 04/23/24
$SLRN
Thuebs89
Posted - 04/23/24
$SLRN unbelievable value here! 3 phase three clinical trials. Excellent pipeline.
Thekking
Posted - 04/22/24
$SLRN I got to believe this is going up... I'm in.
TradeDeskAnalytics
Posted - 04/20/24
$SLRN short squeeze coming to a theater near you.
frontiere
Posted - 04/20/24
@BluntForceOptions hey I’ve see you cheerleading for this one stock on socials. Now make a good bearish case please, preferably 2-3 points at least on why $SLRN is a sell or avoid at current levels 🧏
Thanks!
BluntForceOptions
Posted - 04/19/24
$SLRN 🚨 New 13G SEC filing (Apr 19, 2024): Integrated Core Strategies (US) LLC (newly bought) 4,845,868 common stock, representing 4.93% - 4.99% of the class, with transaction value of approx. $26.89M.
frontiere
Posted - 04/19/24
$SLRN Accelyrin ref=$4.96 long starter with partial stop-loss below 4.8 in case it’s not a bottom… +pending more due dil EOY cash 721 add in 30M refund from CRO =$751M
➔>$200m negative EV (though annual cash burn almost half of cash on hand).
busted IPO, a long saga of weirdness, but IL-17a inhibitor and tons of cash. HS Phase 3 in 2H24
Comp $MLTX Moonlake positive EV=~$2.1B ⁉️
+ comp $VRDN Viridian positive EV=~+300m after Jan financing — whose data they dunk on in their latest deck.
BluntForceOptions
Posted - 04/19/24
$SLRN Diving into my investment approach: I've made numerous incremental buys, starting small and scaling up down here, a method that's served me well by reducing my avg cost effectively. I now hold a sizable position w/ a 5 handle avg. This disciplined approach is rooted in thorough due diligence and strong conviction, which is crucial in managing market volatility—not just enduring it, but leveraging it to my advantage. Despite broader market trends pushing many small caps lower, I view this as an optimal moment to build my positions judiciously, w/ the potential for substantial returns. Acelyrin, at current levels, is a hidden gem, and I firmly believe it's poised to be a multi-bagger once market sentiment shifts—and, IMO, it will. Remember, there's significant institutional backing here, betting long. As the tide turns, I expect the stock to pivot sharply. Here’s to patience and strategy turning into profit! Cheers, y'all, and have a great weekend!
ForestFoxes
Posted - 04/19/24
@Itinerant @Hodlmybitcoin Annex's four-plus year cash runway is a big plus. However, we should remain caution of ALL biotechs and their CEO's. It's only human for us to assign characteristic to CEO's, however I've had some people give me diametrically different impressions of CEO who are in the industry. There are metrics to rate CEO and personalities are not included in them. We are in a risky sector by nature. This is all speculative. $SLRN IPO'ed back in May 2023 and had a value of $3B until a CRO goofed up one of their studies. The company's value dropped down to $0.6B. Review this thread, if you would like details: https://stocktwits.com/ForestFoxes/message/568711742 We are subjected to similar risk in all biotechs that we invest in.
ClassifiedTrades
Posted - 04/19/24
$WISA $SLRN $RWOD WISA 7.9 3rd target hit
ClassifiedTrades
Posted - 04/19/24
$WISA 2nd target $RWOD $SLRN
Trevin102098
Posted - 04/18/24
$SLRN Time for some greeeeennn. I went in heavy today at 4.78. Ready for this bounce back. Goodluck shorts 🚀🚀🚀
BluntForceOptions
Posted - 04/16/24
$SLRN ICYMI: Acelyrin recently reported positive data for its late-stage programs. Both the izokibep and lonigutamab programs are at the forefront in development progress as the next generation approaches to validated mechanisms in psoriatic arthritis (PsA), hidradenitis suppurativa (HS) and thyroid eye disease (TED). Upcoming milestones:
BluntForceOptions
Posted - 04/16/24
$SLRN Recent highlights:
BluntForceOptions
Posted - 04/16/24
$SLRN is now trading at just $5.14. With a MC of $500.33M and an unbelievable $721.33M in cash, the numbers speak for themselves. Each share essentially has $7.40 in net cash, far above the current trading price. On top of this cash cushion, Acelyrin just posted strong results across multiple indications. Despite all these positives, the co's EV stands at a negative $206.40M, signaling a massive undervaluation. For anyone looking at the fundamentals, this is not just a good buy, it's a steal.
TradeDeskAnalytics
Posted - 04/16/24
$SLRN The truth is that retail - dumb money - always sells at exactly the wrong time, while institutional players - smart money - pick up their shares at a huge discount. It’s been like this forever. If you’ve done your hw, these dips are great opportunities. Buy low and sell high. That’s the name of the game, and that’s all that matters - not the other way around. Be patient. As others here have rightfully pointed out, the stock is obviously oversold. A major reversal is coming, and when it does, it will be glorious.
TradeDeskAnalytics
Posted - 04/16/24
$SLRN We’ve been buying the f out of this mispriced security on every dip. Can you say institutional accumulation? Don’t be surprised if we see form 4 insider buying/filings hitting the wire soon. Multibagger by the eoy.
Stonkey
Posted - 04/16/24
$SLRN Red every single bloody day.....
